Preventing stalling to improve CAR-T cells’ efficacy against tumors

Chimeric antigen receptor (CAR)-T cells are a promising cancer therapy that are made from the patient’s own T cells, which are reprogrammed to fight their cancer. One of the limitations of CAR-T cell therapy is the ability of these cells to survive long enough to target the entire tumor.

Leave A Comment

Your email address will not be published. Required fields are marked *